These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7820996)

  • 1. Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus.
    Bonfiglio G; Livermore DM
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):163-6. PubMed ID: 7820996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
    Okhuysen PC; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakpoint determination: piperacillin/tazobactam.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):575-7. PubMed ID: 8404929
    [No Abstract]   [Full Text] [Related]  

  • 11. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
    Reeves DS; Holt HA; Bywater MJ; MacGowan AP
    J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.
    Collins LA; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1994 Jan; 38(1):144-6. PubMed ID: 8141570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.
    Bradford PA; Sanders CC
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2578-83. PubMed ID: 8109919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.